InflaRx drops rare skin disease study for COVID med vilobelimab after futility signal
28th May 2025 Uncategorised 0An independent data monitoring committee assessing a phase 3 trial for InflaRx’s vilobelimab in pyoderma gangrenosum has urged the German drugmaker to stop the study early for futility. Given the trial’s outcome, InflaRx said it plans to stop development of vilobelimab in the rare inflammatory skin disorder.
More: InflaRx drops rare skin disease study for COVID med vilobelimab after futility signal
Source: fierce